



The Nifty previous session ended 0.73% up at 15,690.35. It opened on a flat note and remained range-bound throughout the session towards finishing off in green. Narrow range-bound movement led to another spinning-top candle. Broader uptrend is still intact, so retracement towards critical support may again find buyers. Chart pattern suggests, 15,700-15,750 is likely to act as the thick resistance as of now while the short-term critical support is placed around 15,450 levels. Nifty intraday critical supports are placed around 15,600 and 15,550 levels.

On the Nifty hourly chart, stochastic oscillator recovered from the oversold zone led to intraday recovery and may push the benchmark index further higher towards challenging 15,750.

Nifty patterns on multiple time frames suggest; the benchmark index might get into the trading range of 15,550-15,750. Short-term critical support is placed around 15,450 levels.

### Nifty Crucial Supports & Resistances-

**Supports- 15600, 15550 Resistances- 15700, 15750**

### Open Positional Calls-

T+3 Positional Buy-  
|Cash Segment| PFC @ 117-116,  
TGT- 124, Closing SL- 112

T+3 Positional Buy-  
|Cash Segment| NMDC on dips  
around @ 181-180, TGT- 190, SL-  
closing below 175

T+3 Positional Buy-  
|Cash Segment| M&M FIN on dips  
around @ 158-157, TGT- 167, SL-  
closing below 152

T+10 Positional Buy-  
|Cash Segment| EXIDE on dips  
around @ 192-190, TGT- 210, SL-  
closing below 180

T+5 Positional Buy-  
|Cash Segment| ASHOK LEYLAND @  
123-122, TGT- 132, Closing SL- 117

Key Contents	Page No.
Concall Update	4
Result Update	8
Domestic News	9

## Nifty Intraday Chart



## Market in Retrospect

India's key stock gauge climbed to a new record amid optimism that accelerated vaccination efforts will help revive the economy ravaged by the coronavirus.

Nifty index ended 0.73% higher at 15,690. The broader markets represented by the NIFTY 500 Index ended 0.80% higher, ending at 13,381. Among the sectorial indices, NIFTY Realty was the top gainer, gaining by 3.79%, followed by NIFTY Media, gaining by 1.64% higher. NIFTY Pharma was the top loser, losing by 0.26%

Titan was the top gainer, gaining by 6.65%, followed by ONGC and Eicher Motors which gained by 4.03% & 3.36% respectively. Indusind Bank was the top loser, losing by 2.16%, followed by Wipro and Cipla which fell by 0.73% & 0.68% respectively.

The Advance : Decline ratio stood at 1354:625

## Market Turnover (In Crore) 03-06-2021

Name	Last	Previous
NSE Cash	74704.68	74353.3
NSE F&O	8075404.79	4328023.26
BSE Cash	5,801.34	5,452.16
BSE F&O	*NA	119.90

## FII Derivatives Flow (In Crore) 02-06-2021\*

Instrument	Purchase	Sale	Net
Index Future	2730.62	3837.85	1107.23
Index Option	435858.84	436405.45	546.61
Stock Future	17264.80	17199.81	64.99
Stock Option	13730.64	13739.34	8.7

## Institutional Flow (In Crore) 03-06-2021

Institution	Purchase	Sale	Net
FII	7323.5	6244.3	1079.2
DII	4726	5004.97	278.97

\*Data not updated till 6:00pm

## NIFTY Top Gainers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
Titan	6.65	6.08	7221910	1667147
ONGC	4.03	9.52	64241347	27473470
Eicher Motors	3.36	6.29	1265747	1283201
Larsen & Toubro	2.71	1.89	3025466	2603124
Axis Bank	1.85	0.04	8170508	13219780

## NIFTY Top Losers

Name	%1D	%5D	Day Vol	Avg 5 Day Vol
M&M	0.51	3.20	5001405	9522325
Dr. Reddy'S Lab	0.56	0.26	566718	762822
Cipla	0.68	0.63	2258695	3388815
Wipro	0.73	0.34	5637991	10270910
Indusind Bank	2.16	0.11	14752885	4080818

## Bulk and Block Deals

<https://www.nseindia.com/products/content/equities/equities/bulk.htm>  
<http://www.bseindia.com/markets/equity/EQReports/BulknBlockDeals.aspx>

## Sensex Intraday Chart



## Market in Detailed (Updated after 4:00 PM)

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Sensex	52232.43	382.95	0.74	2.19	7.21	1.53	53.13
Nifty	15690.35	114.15	0.73	2.30	7.22	2.92	55.94
BSE M Cap	22370.45	229.79	1.04	3.15	10.08	7.12	81.27
BSE S Cap	24075.06	248.94	1.04	2.05	9.38	14.18	108.07
Nifty MC 100	26362.55	244.55	0.94	2.56	8.65	7.65	89.33
BSE Auto	23893.25	25.11	0.11	1.61	10.05	0.72	62.33
BSE Capgoods	23021.50	331.66	1.46	1.88	13.00	3.18	79.48
BSE FMCG	13142.05	67.04	0.51	1.14	3.68	6.63	19.07
BSE Metal	18910.21	69.58	0.37	2.92	4.58	29.98	167.34
BSE Oil&Gas	16912.19	208.66	1.25	5.29	13.64	4.66	38.03
BSE Healthcare	24780.94	60.45	0.24	0.42	4.64	14.94	56.47
BSE Power	2880.92	14.22	0.50	2.44	14.68	13.14	89.67
BSE Realty	2813.31	106.86	3.95	6.48	14.86	2.57	80.15
BSE ConsDur	35192.49	1497.14	4.44	5.31	11.09	7.02	68.85
BSE Bank	40419.30	361.82	0.90	1.41	9.33	1.01	67.79
BSE IT	27460.58	86.13	0.31	0.87	4.31	5.85	90.49

### Bond Markets

Name	Yield	Net Chng	%1D	%5D	%1M	%3M	%1Y
US	1.60	0.02	0.96	0.21	0.33	8.24	114.91
UK	0.83	0.03	3.38	1.98	1.90	6.03	201.46
Brazil	3.67	0.07	1.82	2.66	8.33	8.51	23.64
Japan	0.08	0.00	1.21	3.70	13.40	29.41	425.00
Australia	1.67	0.02	1.07	2.15	5.02	0.66	72.00
India	6.00	0.00	0.05	0.03	0.03	3.71	4.02
Switzerland	0.14	0.01	6.25	15.09	35.10	45.57	61.65
Germany	0.19	0.01	5.56	8.72	8.33	35.07	47.18

### Currency

Name	Rate	Net Chng	%1D	%5D	%1M	%3M	%1Y
INR	72.91	0.17	0.24	0.45	1.41	0.26	3.51
USD Index	90.07	0.16	0.18	0.03	0.96	0.97	7.41
YUAN	6.39	0.01	0.15	0.11	1.32	1.21	11.35
GBP	1.42	0.00	0.10	0.15	1.97	1.66	12.80
EUR	1.22	0.00	0.16	0.02	1.06	1.07	8.54
YEN	109.76	0.20	0.18	0.05	0.63	2.51	0.78

### Freight

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Baltic Dry	2530.00	38.00	1.48	9.93	17.13	43.51	327.36
Baltic Dirty	595.00	3.00	0.50	2.46	1.82	10.79	5.25
SG Dubai HY	1.02	0.67	191.43	363.64	38.18	26.62	150.50

### Global Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Dow Jones	34600.38	25.07	0.07	0.84	1.43	10.65	31.71
Nasdaq	13756.33	19.85	0.14	0.73	1.00	5.84	42.07
S&P 500	4208.12	6.08	0.14	0.48	0.37	10.17	34.75
FTSE100	7040.14	64.83	0.91	0.23	1.05	5.51	10.35
CAC40	6493.04	26.42	0.41	0.92	2.97	11.41	29.32
DAX	15518.44	74.54	0.48	0.79	1.91	10.29	24.35
Mexico IPC	50749.64	27.29	0.05	3.35	4.64	9.43	32.54
Brazil Bovespa	129601.4	1334.40	1.04	4.53	8.72	16.56	39.35
Russian RTS	1629.68	16.89	1.03	1.44	9.54	11.91	24.96
Japan Nikkei	29058.11	111.97	0.39	1.78	0.85	1.69	28.50
Hang Seng	28966.03	331.59	1.13	0.51	2.15	3.06	19.08
Taiwan Index	17246.16	81.12	0.47	3.88	0.14	6.38	52.35
Shanghai Comp	3584.21	12.93	0.36	0.68	3.98	0.20	22.61
KOSPI	3247.43	23.20	0.72	2.59	3.84	5.33	51.25
Malaysia KLCI	1590.57	7.37	0.46	0.21	0.01	0.13	3.38
Jakarta Comp	6091.51	59.94	0.99	4.74	2.33	4.47	23.28
Philippine SE	6791.87	49.82	0.73	1.90	6.63	2.17	8.75
Thai Exch	1617.55	1.04	0.06	3.12	2.17	4.80	17.71

### Indian Indices

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
NYMEX Crude	68.63	0.28	0.41	3.53	6.30	11.86	83.83
BRENT Crude	71.21	0.22	0.31	2.79	5.94	13.94	63.97
Natural Gas	3.06	0.02	0.55	1.02	1.46	3.87	19.27

### LME

Name	Index	Net Chng	%1D	%5D	%1M	%3M	%1Y
Gold(\$/Ounce)	1895.63	14.07	0.74	0.12	5.66	10.70	11.45
Silver(\$/Ounce)	27.83	0.38	1.36	0.20	3.29	6.49	57.43
Aluminium	2423.40	26.55	1.08	3.65	0.66	9.73	59.46
Copper	10130.65	103.85	1.01	2.32	3.07	9.87	83.97
Zinc	3061.00	16.00	0.53	3.12	5.07	8.07	51.87
Lead	2234.74	14.99	0.68	3.69	4.57	8.40	31.49

### Agro Commodities

Name	Price	Net Chng	%1D	%5D	%1M	%3M	%1Y
Coffee	161.35	0.20	0.12	3.63	15.04	19.74	49.40
Cotton	84.93	0.27	0.32	2.04	0.32	0.09	42.79
Sugar	17.48	0.20	1.13	4.17	4.48	11.91	44.70
Wheat	694.50	7.00	1.02	7.09	3.27	7.42	29.51
Soybean	1430.75	17.00	1.20	6.22	6.40	16.89	64.79

### PVR Ltd

- There are chances of more Hindi movies releasing compared to South Indian movies after a couple of months, when the unlocking across states may happen, as US, UK and Middle East have reopened. Bulk of the Hindi movies should however release in Q3 and Q4FY22.
- The experience of releasing Salman Khan starrer, Radhe on OTT has not been great. This was the first big Hindi movie to have released on OTT and the experiment failed. The Management of PVR is of the view that this was a one off and since the experiment was not successful most big budget producers, if not all would wait for a theatrical release as that is where 60-70% of the revenue is generated.
- The pandemic may have been hard on the single screen operators, who don't have other channels of revenue. Out of a total of 9000 screens, 3000 belong to multiplexes and the Management of PVR expects 10% of single screens to have been permanently shut. In the next 3-4 years, small exhibitors including single screen operators may struggle and large multiplex operators would see more growth. There would be consolidation opportunities across the industry. Growth of multiplexes would be driven by growth of malls.
- The Management was not ready to commit to a figure related to monthly cash burn. Post 31st of March, the Management is again negotiating with landlords with respect to rental waivers and discounted CAM and they expect a large relief. Cost reduction drives similar to the one witnessed during the first wave have been reinitiated. On a normalised basis there would be a 10-15% reduction in people and overhead costs compared to FY20 when situation reverts to normal.
- 19 screens are ready for immediate reopening. Apart from that, the Management was not ready to guide on a capex amount for FY22. However, long term screen additions plans are still intact and there is a possibility that only 10% of the long term cumulative figure may not see the light of the day as malls connected with those may not get constructed.
- The Company would still remain in the 35% tax category for the next 2-3 years as they have MAT credit. Post 2-3 years, the Company would move to 25% tax rate.
- Long term loans of the Company are spread over 4-5 years and there would be a repayment of INR2000-3000 mIn every year. Current liquidity of the Company is around INR7500 mIn.
- The Management is of the opinion that the bulk of the producer community is not under financial stress because of their movies not releasing. Even actors have not reduced their fees.
- The release of South Indian movies during Q4FY21 were not at reduced ATP. Even SPH level was comparable to pre Covid times. There was no market share loss by PVR. In a normalised scenario 35-36% of box office revenues are contributed by South Indian movies.
- The Management is of the view that advertising revenues will follow footfalls as was seen in South Indian releases like Master. The Management will not offer discounted rates to advertisers.



### Balrampur Chini Mills Ltd.

#### Sugar Production-

- For SS 20-21, India's sugar production is estimated at ~30.8 MMT, net of sugar sacrifice of ~2.0 MMT for production of Ethanol.
- During SS20-21, sugar production in Uttar Pradesh is estimated ~11 MMT as compared to 12.5 MMT produced last year. Maharashtra is expected to produce ~10.6 MMT as compared to 6.2 MMT (YoY). Karnataka production is estimated at ~4.2 MMT as compared to 3.4 MMT (YoY).

#### Sugar Export-

- 5.70 MMT of sugar has already been contracted for export for the SS 2020-21.
- The industry is also expected to export under the OGL (open general license), taking the total export quantity to ~6 MMT

#### Global sugar production-

- Brazil is expected to produce much lower sugar in the current season on account of dry weather conditions.
- On the back of firm international prices, even the domestic sugar prices are expected to see improvement from the current levels of INR~33.5/kg
- Current NY11 raw sugar price (July contract) is ~17 c/lb which would translate to INR26.5/kg for UP based sugar mills without financial assistance.
- Similarly, London white sugar price (Oct contract) is ~\$448.5/MT which would translate to INR29.5/kg for UP based sugar mills without financial assistance.

#### Operational performance-

- For the SS20-21 company opted for trading of export quota instead of engaging in physical exports which resulted in lower revenue for Q4FY21.
- In Q4FY21, company sold 19.27 lac qtls, which was less than its domestic quota of 21 lac qtls.
- Company diverted 65.4% sugarcane to B-heavy molasses during FY21 as compared to 32.0% during FY20 resulting in sugar sacrifice of 11.7 lac quintals as compared to 5.1 lac quintals in previous year.
- The company is reducing its dependence on co 238 variety and shifting its dependence to other high sucrose yielding varieties such as co 118 and others.
- Company expects to crush 950 lac qtls of sugarcane in FY22 and expects a sugar recovery of 11.79% in FY22.

- The company is holding 644 mn kg of sugar valued at INR31.28/kg as on 31st March 2021 against 684.8 mn kg valued at INR29.49/kg in March 2020.
- Cane dues as of 31st March '21 stood at INR180 crore and receivables from UPPTCL & GOI on account of power dues and export subsidy is INR80 crore and INR150 crore respectively.
- OMC has finalized tenders for 346.52 crore litres out of which 318.10 crore litres has been contracted till date.
- Board of Directors recently approved an investment of INR425 crore for the new 320 KLPD distillery (multi-feed raw material) facility that is scheduled to commence operations from December 2022. Annual revenue from this plant is expected to be ~INR650 crore and pay-back is expected to be less than 4 years.

### Narayana Hrudayalaya Ltd.

#### India Update

- Covid contributed to 3% of domestic revenues in Q4FY21. The figure was 14.2% in Q3FY21.
- The domestic revenue mix is witnessing more contribution from oncology through higher growth while cardiac retains the lion's share. Oncology will soon replace gastro sciences from the second highest contributor of revenue.
- The Management is cautious with regard to the second wave of Covid. However, June is witnessing a return to normalcy with elective surgeries picking up. While 2% of domestic revenues was attributed to Covid in March 2021 (March 2021 also witnessed 112% of February 2020 domestic revenue). April 2021 saw that number rise to 13%. The percentage for May 2021 would be even higher. Domestic revenues in April 2021 were down by 7% compared to March 2021. Normally, April witnesses a 3-4% de-growth compared to March. Domestic revenues in May 2021 were another 3-4% below that of April.
- Narayana has been on a capex consolidation mode in the last two financial years. No greenfield or brownfield capex happened and capex was restricted to addition of new wings and changes in ward mix. While the situation would remain more or less the same in the next two to three years in India there would be some dedicated capex in Bangalore, Howrah and Kolkata. In FY22 a capex in the range of INR2500-INR3000 mln has been planned for India. Narayana is very conscious about its capital allocation policy and looks out for superior return on capital, which in their opinion is better in the Caribbean region than in India.
- The flagship centres in India are expected to show a high single digit revenue growth rate for the next 2-3 years while other centres in India will have a low double digit growth.

- Narayana is not making any money on the vaccination drive project across India. It is charging from the patients the exact amount that it is paying to the vendors like Serum Institute of India and Bharat Biotech. Between 3-5 lakhs doses would be administered per month for at least the next nine months across Narayana facilities in India.
- The Management did not guide concretely with regard to the sustenance of India ARPOB at INR11 mln as was reported in Q4FY21. However, in a normalised scenario it believes that the ARPOB would go down given the return of Government patients and less number of high end procedures compared to what was witnessed in Q4FY21. However, increasing contribution from oncology will push up the ARPOB.
- Consolidated EBITDA margins should also fall from the reported 16.9% in Q4FY21.
- Mumbai and Gurugram hospitals should break even by FY22.
- India discharges have room to pick up once the situation normalises.

### Cayman Update

- Cayman islands will continue to generate 70-80% of revenues from locals and balance from international patients.
- Capex and development of project in Cayman is going on as per plan. Narayana is prioritising speed over costs in negotiating with contractors. The whole project with regard to the new facility will be ready in 24 months. There is also an emphasis in opening new clinics across Cayman. These come at a capex of USD 0.5 to 1 mln dollars. Other islands in the Caribbean region are inviting Narayana to come and have discussions with regard to opening hospitals in their islands.

### MTAR Technologies Limited

MTAR Technologies Limited reported its profit after tax was up by 47 per cent to INR46.1 crore in FY21 against INR31.3 crore in the year ago period. In a press release, the city-based firm said revenue from operations stood at INR246.40 crore in FY21 as against INR213.80 crore in FY20, up by 15 per cent.

### APL Apollo Tubes

APL Apollo Tubes Limited (APL Apollo) reported its financial results for the quarter and full-year ended March 31, 2021. The company's sales volume rose by 9% yoy to 435 k tons in Q4FY21 compared to 401 k tons in Q4FY20. Company's EBITDA up by 72% to INR2.1bn. EBITDA per ton was INR4,742 (+58% yoy). Interest Cost declined by 40% to INR143mn. Net Profit as up by 110% to INR1.2 bn. During FY21, Sales Volume as higher by 0.4% to 1.6 Mn tons. Revenue increased 10% to INR85 bn. EBITDA higher by 42% to INR6.8 bn. EBITDA per ton was INR4,138 (+42% yoy). Net Profit up by 51% to INR3.6bn. Net debt declined to INR1.6 bn from INR7.9 bn.

### Arvind Fashion

Arvind Fashions Limited (AFL) reported Q4 FY21 revenue grew by 14% with marginally positive LTL store sales. This was driven by strong recovery across the channels and increased footfalls in the stores. It was further aided by continued traction in the online channel. Power brands posted growth of 17% with significantly improved profitability on yoy and qoq basis. USPA & Tommy Hilfiger sales recovery was strongest at 125% delivering double digit EBITDA (pre-IndAS) Sephora sales recovery was 114% led by both offline & online channels. Strong sales growth coupled with efficient cost management enabled the company to deliver 98% growth in EBITDA for continuing business at 97cr in Q4 FY21 compared to 49cr in Q4 FY20.

### Nilkamal

Net profit of Nilkamal rose 19.84% to INR38.06 crore in the quarter ended March 2021 as against INR31.76 crore during the previous quarter ended March 2020. Sales rose 21.10% to INR679.92 crore in the quarter ended March 2021 as against INR561.46 crore during the previous quarter ended March 2020. For the full year, net profit declined 20.52% to INR112.93 crore in the year ended March 2021 as against INR142.08 crore during the previous year ended March 2020. Sales declined 7.31% to INR2092.20 crore in the year ended March 2021 as against INR2257.19 crore during the previous year ended March 2020.



### **India brings forward target of 20 percent ethanol-blending in petrol to 2023**

The government has brought forward the target date for achieving 20 per cent ethanol-blending with petrol by two years to 2023 to help reduce India's dependence on costly oil imports, according to official notification. Last year, the government had set a target of reaching 10 per cent ethanol-blending in petrol (10 per cent of ethanol mixed with 90 per cent of diesel) by 2022, and 20 per cent doping by 2030. Earlier this year, the target for 20 per cent blending was brought forward to 2025. India is the world's third-biggest oil importer, relying on foreign suppliers to meet over 85 per cent of its demand. In the current ethanol supply year, which started in October, India plans to have 10 per cent ethanol-blending with gasoline. As much as 4 billion litres of ethanol will be needed for achieving a 10 per cent mixing ratio.

### **Tata Steel provides 300 oxygen concentrators to Jharkhand government to help fight COVID-19**

Tata Steel has provided 300 oxygen concentrators to the Jharkhand government to help it fight against the second wave of COVID-19. These oxygen concentrators were imported from the US and China. These oxygen concentrators were given to the state government's health, medical education and family welfare department additional chief secretary AK Singh.

### **Steel becomes costlier; companies hike rates by up to INR4,900/tonne in India**

Leading domestic steel makers have hiked the prices of Hot Rolled Coil (HRC) and Cold Rolled Coil (CRC) by up to INR4,000 and INR4,900 per tonne, respectively, industry sources said on Thursday. After the price revision, a tonne of HRC will cost INR70,000-71,000 while the buyers will get CRC at INR83,000-84,000 per tonne. The price revision has been made in the last two days. HRC and CRC are flat steel used in industries such as auto, appliances and construction. Hence, any rise in steel prices impacts the prices of vehicles, consumer goods and cost of construction as steel is a raw material for these sectors. Global Steel prices have moved up owing to a spike in the cost of raw materials. Indian iron ore has gone up by INR4000/tonne which is also pushing steel prices higher.

### **Zydus Cadila gets tentative USFDA nod to market lung cancer treatment drug**

Zydus Cadila has received tentative approval from the US health regulator to market Osimertinib tablets, used to treat lung cancer. The company has received tentative approval from the US Food and Drug Administration (USFDA) to market Osimertinib tablets in the strengths of 40 mg and 80 mg, Zydus Cadila, part of the Cadila Healthcare group. Osimertinib is used to treat lung cancer. Osimertinib works by slowing or stopping the growth of cancer cells. The company said the newly approved medication will be manufactured at the group's formulation manufacturing facility at the SEZ, Ahmedabad. The group now has 318 approvals and has so far filed over 400 abbreviated new drug applications since the commencement of the filing process in financial year 2003-04.

### **Sterlite Copper to produce 400 medical grade oxygen cylinders a day at Tamil Nadu facility**

Sterlite Copper Plant has commissioned a new oxygen cylinder bottling unit to produce 400 medical grade oxygen cylinders a day, at its facility in Tamil Nadu that has been set up at an outlay of INR11 crore. Employees and partners worked together to activate the facility within a day of receiving the required materials and machinery to set up the oxygen cylinder bottling plant.

### **Airtel deploys additional 20 MHz spectrum in Haryana to boost network**

Bharti Airtel has deployed additional 20 MHz spectrum in the 2300 MHz band in Haryana to deliver better network experience to its customers. The additional spectrum will bolster high-speed data capacity in its network and enable improved network availability and data speeds in urban and rural areas. The deployment also allows Airtel to offer wider coverage along highways and rail routes as well as increase footprint in villages as more people access high speed data services. With the addition of this fresh spectrum acquired during the latest spectrum auctions, Airtel has the largest spectrum bank of 71.2 MHz in Haryana.

### CORPORATE ACTION BONUS / RIGHTS / STOCK SPLIT / DIVIDEND / FCCB / M&A / WARRANTS ETC.

Company	Details
Manappuram Finance Ltd	Cash dividend of INR0.75 effective 04-06-2021
Ksolves India Ltd	Stock dividend of INR4 effective 04-06-2021
Ksolves India Ltd	Cash dividend of INR30 effective 04-06-2021
Cigniti Technologies Ltd	Corporate meeting effective 04-06-2021
Supreme Infrastructure India Ltd	Corporate meeting effective 04-06-2021
Shah Construction Co Ltd	Corporate meeting effective 04-06-2021
Zicom Electronic Security Systems Ltd	Corporate meeting effective 04-06-2021

### Domestic Events

- **Upcoming Result's:-** Bank Of India, Bharat Forge Ltd., Moil Ltd., NIIT Ltd.
- India RBI Interest Rate Decision.
- India Foreign Exchange Reserve for May 28, 2021.

### Global Events

- Euro Area Retail Sales for April 2021.
- Japan Household Spending for April 2021.
- The U.S. Unemployment Rate for May 2021.

Source of News : The content may have been taken from The Economic Times, Business Standard, Business Line, Mint and other leading financial newspapers and financial portals BSE,NSE, Bloomberg, Moneycontrol & others.

### **Analyst Certification:**

We /I, Deepankar Saha & Jaydeb Dey Research Analyst(s) of SMIFS Limited (in short “SMIFS / the Company”), authors and the names subscribed to this Research Report, hereby certify that all of the views expressed in this Research Report accurately reflect our views about the subject issuer(s) or securities and distributed as per SEBI (Research Analysts) Regulations 2014. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this Research Report. It is also confirmed that We/I, the above mentioned Research Analyst(s) of this Research Report have not received any compensation from the subject companies mentioned in the Research Report in the preceding twelve months and do not serve as an officer, director or employee of the subject companies mentioned in the Research Report.

### **Terms & Conditions and Other Disclosures:**

SMIFS Limited is engaged in the business of Stock Broking, Depository Services, Portfolio Management and Distribution of Financial Products. SMIFS Limited is registered as Research Analyst Entity with Securities & Exchange Board of India (SEBI) with Registration Number – INH300001474.

SMIFS and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Research Analysts. SMIFS generally prohibits its analysts, persons reporting to analysts and their relatives from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

The information and opinions in this Research Report have been prepared by SMIFS and are subject to change without any notice. The Research Report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of SMIFS Limited. While we would endeavor to update the information herein on a reasonable basis, SMIFS is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent SMIFS from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or policies of SMIFS, in circumstances where SMIFS might be acting in an advisory capacity to this company, or in certain other circumstances.

This Research Report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This Research Report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Securities as defined in clause (h) of section 2 of the Securities Contract Act, 1956, includes Financial Instruments, Currency and Commodity Derivatives. Though disseminated to all the customers simultaneously, not all customers may receive this Research Report at the same time. SMIFS will not treat recipients as customers by virtue of their receiving this Research Report. Nothing in this Research Report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this Research Report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. SMIFS accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this Research Report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice. The information given in this report is as of date of this report and there can be no assurance that future results or events will be consistent with this information. The information provided in this report remains, unless otherwise stated, the copyright of SMIFS. All layout, design, original artwork, concepts and intellectual Properties remains the property and copyright of SMIFS and may not be used in any form or for any purpose whatsoever by any party without the express written permission of the SMIFS.

SMIFS shall not be liable for any delay or any other interruption which may occur in presenting the data due to any reason including network (Internet) reasons or snags in the system, breakdown of the system or any other equipment, server breakdown, maintenance shutdown, breakdown of communication services or inability of SMIFS to present the data. In no event shall SMIFS be liable for any damages, including without limitation direct or indirect, special, incidental, or consequential damages, losses or expenses arising in connection with the data presented by the SMIFS through this report.

Participants in foreign exchange transactions may incur risks arising from several factors, including the following: (a) Exchange Rates can be volatile and are subject to large fluctuations; (b) the value of currencies may be affected by numerous market factors, including world and notional economic, political and regulatory events, events in Equity & Debt Markets and changes in interest rates; and (c) Currencies may be subject to devaluation or government imposed Exchange Controls which could affect the value of the Currency. Investors in securities such as Currency Derivatives, whose values are affected by the currency of an underlying security, effectively assume currency risk.

Since associates of SMIFS are engaged in various financial service businesses, they might have financial interests or beneficial ownership in various companies including the subject company/companies mentioned in this Research Report.

SMIFS and its Associates, Officers, Directors, Employees, Research Analysts including their relatives worldwide may: (i) from time to time may have long or short positions in, and buy or sell the Securities, mentioned herein or (ii) be engaged in any other transaction involving such Securities and earn brokerage or other compensation or act as a market maker in the Financial Instruments of the Subject Company/ companies mentioned herein or act as an Advisor or Lender/Borrower to such Companies or have other potential/material Conflict of Interest with respect to any recommendation and related information and opinions at the time of the publication of the Research Report. Or at the time of Public Appearance. SMIFS does not have proprietary trades but may at a future date, may opt for the same with prior intimation to Clients/ Investors and extant Authorities where it may have proprietary long/ short position in the above Scrip(s) and therefore should be considered as interested. The views provided herein are general in nature and do not consider Risk Appetite or Investment Objective of any particular Investor; Clients/ Readers/ Subscribers of this Research Report are requested to take independent professional advice before investing. The information provided herein should not be construed as invitation or solicitation to do business with SMIFS.

SMIFS or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the Research Report as of the last day of the month preceding the publication of the Research Report.

SMIFS encourages independence in Research Report preparation and strives to minimize conflict in preparation of Research Report. Accordingly, neither SMIFS and their Associates nor the Research Analysts and their relatives have any material conflict of interest at the time of publication of this Research Report or at the time of the Public Appearance, if any.

SMIFS or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

SMIFS or its associates might have received any compensation from the companies mentioned in the Research Report during the period preceding twelve months from the date of this Research Report for services in respect of managing or co-managing public offerings, corporate finance, investment banking, brokerage services or other advisory service in a merger or specific transaction from the subject company.

SMIFS or its associates might have received any compensation for products or services other than investment banking or brokerage services from the subject companies mentioned in the Research Report in the past twelve months.

SMIFS or its associates or its Research Analysts did not receive any compensation or other benefits whatsoever from the subject companies mentioned in the Research Report or third party in connection with preparation of the Research Report.

Compensation of Research Analysts is not based on any specific Investment Banking or Brokerage Service Transactions.



The Research Analysts might have served as an officer, director or employee of the subject company.

Neither the Research Analysts nor SMIFS have been engaged in market making activity for the companies mentioned in the Research Report.

SMIFS may have issued other Research Reports that are inconsistent with and reach different conclusion from the information presented in this Research Report.

A graph of daily closing prices of the securities/commodities is also available at [www.nseindia.com](http://www.nseindia.com) and/or [www.bseindia.com](http://www.bseindia.com), [www.mcxindia.com](http://www.mcxindia.com) and/or [www.icex.com](http://www.icex.com).

SMIFS submit' s that no material disciplinary action has been taken on the Company by any Regulatory Authority impacting Equity Research Analysis activities in last 3 years.

This Research Report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject SMIFS and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

For queries related to compliance of the report, please contact: -

**Sudipto Datta, Compliance Officer**

**SMIFS Limited.**

**Vaibhav, 4 Lee Road, Kolkata 700020, West Bengal, India.**

**Contact No.: +91 33 4011 5414 /91 33 6634 5414**

**Email Id.: [compliance@smifs.com](mailto:compliance@smifs.com)**

**Website: [www.smifs.com](http://www.smifs.com)**